Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best stocks to buy and ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...